Personalizing A1c Using Hematologic Indices and CGM for Accurate Diabetes Diagnosis
PRECISE DM DX
1 other identifier
observational
45
0 countries
N/A
Brief Summary
The goal of this observational study is to learn why some adults over the age of 65, have A1c tests that do not match up with their blood glucose levels, also known as 'A1c-glucose discordance'. The main question it aims to answer is: Could alternative tests like CGM or personalized A1c provide more accurate diabetes screening in this population? Participants will be asked to perform blood tests every week to two weeks and wear a CGM for up to 8 weeks.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P25-P50 for all trials
Started Sep 2025
Shorter than P25 for all trials
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
August 1, 2025
CompletedFirst Posted
Study publicly available on registry
August 8, 2025
CompletedStudy Start
First participant enrolled
September 1, 2025
CompletedPrimary Completion
Last participant's last visit for primary outcome
April 1, 2026
CompletedStudy Completion
Last participant's last visit for all outcomes
May 1, 2026
CompletedAugust 8, 2025
August 1, 2025
7 months
August 1, 2025
August 1, 2025
Conditions
Outcome Measures
Primary Outcomes (1)
Calculate the Mean Absolute Difference Between A1c-Derived Estimated Average Glucose (eAG) and CGM-Derived eAG
Determine the mean absolute difference between estimated average glucose (eAG) calculated from hemoglobin A1c and eAG derived from Continuous Glucose Monitoring (CGM) data. This measure will be assessed among participants suspected of having discordance between A1c values and actual blood glucose levels.
From 1 week after enrollment to the end of their enrollment at either week 5 or week 10
Eligibility Criteria
Individuals 65 years of age and older, who have evidence of A1c-glucose discordance without either a diagnosis of type 2 diabetes or current/ prior treatment for type 2 diabetes
You may qualify if:
- Age 65 years of age or older
- A1c 5.3% - 7.4% without a diagnosis on the problem list and/or current or prior treatment for diabetes
- Evidence of A1c discordance by meeting one of two criteria developed by an EHR based algorithm
- At least five (5) HbA1c values and three (3) CBC values available in the EHR in the previous 10 years
- Willingness to wear an Abbott Freestyle Libre 3 System Sensor for up to 48 days
- Willingness to consent to data collection using the electronic health record and sign a medical release to obtain future medical records from other health care facilities
You may not qualify if:
- Known or suspected diabetes of other causes (type 1 diabetes, pancreatogenic diabetes, monogenic diabetes, etc.)
- Clinically significant anemia based on most recent hematocrit (M = \<38%, F \<33%) and/or hemoglobin (M = \<12 g/dL, F = \<10 g/dL) within the last 12 months
- Condition with short life expectancy
- Blood (hematologic) malignancy
- rtCGM-interference agents per manufacturer (e.g., high dose vitamin C)
- Unstable psychiatric or medical condition
- Active treatment for cancer, planned treatment for cancer, or recent active cancer with a likelihood of recurrence or progression, that, in the opinion of the site investigator, would interfere with study therapy prior to 2029
- Allowed Exceptions: Treated cancer with no evidence of disease, no evidence of disease progression, and no planned change in therapy. Examples of allowable cancers include:
- Breast cancer stable after active treatment, managed with long-term anti-estrogen therapy
- Prostate cancer being observed
- Stage 0 or 1 tumors status post resection or other definitive treatment
- Other similarly stable cancer comorbidities
Contact the study team to confirm eligibility.
Sponsors & Collaborators
- Brigham and Women's Hospitallead
- Abbott Diabetes Carecollaborator
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Design
- Study Type
- observational
- Observational Model
- COHORT
- Time Perspective
- PROSPECTIVE
- Sponsor Type
- OTHER
- Responsible Party
- PRINCIPAL INVESTIGATOR
- PI Title
- Associate Professor
Study Record Dates
First Submitted
August 1, 2025
First Posted
August 8, 2025
Study Start
September 1, 2025
Primary Completion
April 1, 2026
Study Completion
May 1, 2026
Last Updated
August 8, 2025
Record last verified: 2025-08